Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss and diabetes drugs has been resolved.
The FDA website indicated that the shortage of Novo Nordisk's Ozempic and Wegovy has ended. The announcement is bad news for Hims & Hers, a compounding pharmacy that makes a knockoff version of Wegovy.
In December, the FDA said Eli Lilly (LLY) drugs Mounjaro and Zepbound were no longer in shortage.
↑ X NOW PLAYING Nvidia Earnings Preview: Blackwell, DeepSeek And Big ExpectationsHims (HIMS) stock crashed nearly 20% to 53.38 in morning trades after hitting a record 72.98 on Wednesday. Shares of Novo Nordisk (NVO) rallied 5.1% to 88.03, just below a long-sliding 50-day line. Eli Lilly stock rose 1.7% to 888, near an 889.36 handle buy point.
Hims stock, which has rallied more than 120% this year, is on track to record its first weekly loss in six weeks, according to IBD MarketSurge. The shares have had a strong Relative Strength rating of 99.
The news underlines the role played by compounders, companies allowed to create knockoffs of drugs to offset shortages, in the fast-growing weight-loss drugs industry.
Hims & Hers also recently took some heat for a Super Bowl ad that does not include any warnings about the side effects of Wegovy.
Him & Hers will report Q4 results on Monday.
YOU MAY ALSO LIKE:
Get Timely Buy & Sell Alerts With IBD Leaderboard
Uber Stock Eyes Bounce Back As Robotaxi Strategy Faces Big Test
Which Stocks Are Breaking Out Or Near A Pivot Point? Check MarketSurge
Nvidia Stock Pauses Despite Debut Of Blackwell. What The King Of AI Chips Needs Now.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.